Multiplex Assay Kit for Angiotensinogen (AGT) ,etc. by FLIA (Flow Luminescence Immunoassay) 
ANHU; SERPINA8; Angiotensin; Renin Substrate; Serpin Peptidase Inhibitor,Clade A,Member 8(Alpha-1 Antiproteinase,Antitrypsin)
(Note: Up to 8-plex in one testing reaction)
- UOM
- FOB US$ 405.00 US$ 420.00 US$ 443.00 US$ 475.00 US$ 506.00 US$ 552.00 US$ 622.00 US$ 778.00
- Quantity
Overview
Properties
- Product No.LMA797Mu
- Organism SpeciesMus musculus (Mouse) Same name, Different species.
- ApplicationsFLIA Kit for Antigen Detection.
Research use only - DownloadInstruction Manual
- CategoryCardiovascular biology
Sign into your account
Share a new citation as an author
Upload your experimental result
Review
Contact us
Please fill in the blank.
-
Packages (Simulation)
-
Packages (Simulation)
-
Results demonstration
-
Typical Standard Curve
-
ISO9001: 2008, ISO13485: 2003 Registered
Recovery
Matrices listed below were spiked with certain level of recombinant Angiotensinogen (AGT) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Angiotensinogen (AGT) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 99-105 | 102 |
| EDTA plasma(n=5) | 93-101 | 96 |
| heparin plasma(n=5) | 94-102 | 98 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Angiotensinogen (AGT) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Angiotensinogen (AGT) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Angiotensinogen (AGT) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 82-101% | 84-101% | 89-101% | 94-103% |
| EDTA plasma(n=5) | 88-104% | 78-101% | 91-102% | 82-90% |
| heparin plasma(n=5) | 80-102% | 83-95% | 96-104% | 90-98% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| 96-well plate | 1 | Plate sealer for 96 wells | 4 |
| Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
| Pre-Mixed Magnetic beads (22#:AGT) | 1 | Analysis buffer | 1×20mL |
| Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
| Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
| Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
| Instruction manual | 1 |
Assay procedure summary
1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.
Test principle
Analyte-specific antibodies are pre-coated onto color-coded microparticles. Microparticles, standards, and samples are pipetted into wells and the immobilized antibodies bind the analytes of interest. After washing away any unbound substances, a biotinylated antibody cocktail specific to the analytes of interest is added to each well. Following a wash to remove any unbound biotinylated antibody, Streptavidin-Phycoerythrin conjugate (Streptavidin-PE), which binds to the biotinylated detection antibodies, is added to each well. A final wash removes unbound Streptavidin-PE and the microparticles are resuspended in buffer and read using the Luminex or Bio-Plex analyzer.The MFI developed is proportional to the concentration of analytes of interest in the sample.
Giveaways
Increment services
Citations
- Elevated urinary angiotensinogen a marker of intrarenal renin angiotensin system in hypertensive renal transplant recipients: does it play a role in development of proteinuria in hypertensive renal transplant patients?Wiley: source
- The relation between urinary angiotensinogen and proteinuria in renal AA amyloidosis patientsPubMed: 22320202
- Urinary angiotensinogen as a marker of intrarenal angiotensin II activity in adolescents with primary hypertensionPubMed: PMC3661928
- Urinary angiotensinogen as a novel marker of obstructive nephropathy in childrenPubmed: 23772991
- Association between urinary angiotensinogen, hypertension and proteinuria in pregnant women with preeclampsiaSagepub: Source
- MP707 CHARACTERISTICS AND OUTCOMES OF CHILDREN WITH AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE COHORT FROM THE ESPN/ERA-EDTA REGISTRYOxfordjournals:Source
- Relationship between blood pressure varPubMed: 26223347
- Higher Serum Angiotensinogen Is an Indicator of IgA Vasculitis with Nephritis Revealed by Comparative Proteomes AnalysisPubMed: 26098644
- Korelasi pengukuran antropometri dengan tekanan darah dan angiotensinogen plasma pada dewasaIndex.Php: Art
- Relationship between blood pressure variability and renal activity of the renin-angiotensin system.pubmed:26223347
- Pharmacological evidence: a new therapeutic approach to the treatment of chronic heart failure through SUR2B/Kir6.1 channel in endothelial cells.pubmed:27890915
- Application of a new procedure for liquid chromatography/mass spectrometry profiling of plasma amino acid-related metabolites and untargeted shotgun proteomics to identify mechanisms and biomarkers of calcific aortic stenosisS0021967317311858
- Pyrrolidine dithiocarbamate inhibits mouse acute kidney injury induced by diclofenac by targeting oxidative damage, cytokines and NF-κB activityPubmed:30036488
- Role of (Pro) Renin Receptor in Albumin Overload-Induced Nephropathy in RatsPubmed:29846109
- Quantitation of Total and Free Thiol Angiotensinogen as a Prognostic Marker for PreeclampsiaPubmed: 31069778
- Multi-omic signatures of atherogenic dyslipidaemia: pre-clinical target identification and validation in humans33407555
- Association of Ang-(1¨C7) and des-Arg 9 BK as new biomarkers of obesity and cardiometabolic risk factors in adolescents33568792
- (Pro) renin receptor antagonist PRO20 attenuates nephrectomy©\induced nephropathy in rats via inhibition of intrarenal RAS and Wnt/¦Â©\catenin signaling34057312
- A novel strategy to identify candidate diagnostic and prognostic biomarkers for gastric cancer34215253